Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Saved in:
| Title: | Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design. |
|---|---|
| Authors: | Nickerson, Peter W.1 (AUTHOR), Böhmig, Georg A.2 (AUTHOR), Chadban, Steve3 (AUTHOR), Kumar, Deepali4 (AUTHOR), Mannon, Roslyn B.5 (AUTHOR), van Gelder, Teun6 (AUTHOR), Lee, James C.7 (AUTHOR) james.lee2@cslbehring.com, Adler, Scott7 (AUTHOR), Chong, Edward7 (AUTHOR), Djamali, Arjang8 (AUTHOR) |
| Source: | Trials. 12/22/2022, Vol. 23 Issue 1, p1-12. 12p. 1 Diagram, 4 Charts. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17456215 |
|---|---|
| DOI: | 10.1186/s13063-022-06897-3 |
